KalVista Pharmaceuticals, Inc.
KALV
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVDā¦ read more
Healthcare
Biotechnology
10 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$15.81
Price-2.14%
-$0.34
1Y
Price
Market Cap
$798.884m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-308.2%
EBITDA Margin-361.4%
Net Profit Margin-238.9%
Free Cash Flow Margin-308.2%
EBITDA Margin-361.4%
Net Profit Margin-238.9%
Free Cash Flow MarginRevenue
$15.118m
-
1y CAGR-
3y CAGR-
5y CAGREarnings
-$210.313m
-14.6%
1y CAGR-31.9%
3y CAGR-27.2%
5y CAGREPS
-$4.01
-8.7%
1y CAGR-6.4%
3y CAGR-4.6%
5y CAGRBook Value
$16.999m
$339.931m
Assets$322.932m
Liabilities$149.585m
DebtDebt to Assets
44.0%
-0.8x
Debt to EBITDAFree Cash Flow
-$160.319m
-4.5%
1y CAGR-30.9%
3y CAGR-22.4%
5y CAGRNo items found.
Press Releases
Statements and updates from the company